STOCK TITAN

IQVIA Holdings (IQV) Stock News

IQV NYSE

IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.

Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.

News
Rhea-AI Summary

IQVIA (NYSE: IQV) reported third-quarter 2026 revenue of $4,428 million, up 8.0% year over year, and raised its full-year outlook. GAAP net income attributable to IQVIA rose to $350 million from $331 million, while diluted earnings per share increased to $2.10 from $1.93. Adjusted EBITDA rose 8.7% to $1,032 million; adjusted diluted earnings per share increased 11.3% to $3.34.

Commercial Solutions revenue grew 6.9% to $1,789 million, and R&D Solutions revenue rose 8.7% to $2,639 million. Quarterly net new bookings increased 15% to $3.2 billion. An inactive-trial review reduced backlog by approximately $2.1 billion, leaving $32.6 billion. Free cash flow was $667 million. IQVIA now expects 2026 revenue of $17,350 million–$17,500 million, adjusted EBITDA of $4,025 million–$4,055 million and adjusted diluted earnings per share of $12.90–$13.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
Rhea-AI Summary

IQVIA (IQV) expanded its partnership with Veeva Systems (VEEV), selecting four Veeva applications as enterprise standards across its clinical development studies. The selected applications are CTMS, eTMF, Study Startup and Site Connect. They will be used across IQVIA studies, extending the companies' previously announced electronic data capture partnership.

All Veeva clinical solutions are also available through IQVIA for sponsors seeking a full Veeva technology stack. IQVIA said the collaboration is intended to give clinical teams a more connected way to work through integration of the companies' technologies. Customers retain flexibility to choose electronic data capture, randomization and trial supply management, and electronic clinical outcome assessment technologies, including IQVIA solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary

IQVIA (IQV) introduced IQVIA Life Science Models at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. The models use technologies including NVIDIA Nemotron and are supported by Amazon Web Services infrastructure. They connect molecular and treatment information with patient journeys and clinical outcomes. In an initial evaluation across 50 trials and 270 endpoints, 85% of predictions were on target or clinically close.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
Rhea-AI Summary

IQVIA (IQV) introduced IQVIA Explorer at TechIQ 2026 to support commercial decision-making for life sciences customers. The tool combines IQVIA data, analytical methods and workflows to answer business questions using external indicators.

IQVIA says Explorer provides near real-time intelligence for analyzing brand performance, identifying where to focus commercial resources and testing revised assumptions. Its examples include analysis of treatment starts, switching and discontinuation across patient populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
none
-
Rhea-AI Summary

IQVIA (NYSE: IQV) will announce its third-quarter 2026 financial results before the market opens on October 27, 2026.

Management will host a conference call and webcast at 9:00 a.m. Eastern Time that day. The earnings release, accompanying financial information and webcast will be available on IQVIA’s Investor Relations website. A webcast replay will be available approximately two hours after the live event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
earnings date
-
News
Rhea-AI Summary

IQVIA (IQV) priced a private offering of $2.0 billion aggregate principal amount of senior notes due 2034 through its subsidiary IQVIA Inc.

The Notes will bear interest at 6.375% per annum, with semi-annual payments each March 15 and September 15, starting March 15, 2027, and will mature on March 15, 2034, unless earlier repurchased or redeemed. IQVIA plans to use the proceeds to redeem in full its Senior 5.000% Notes due 2026, repay a portion of borrowings under its revolving credit facility, and pay related fees and expenses. Issuance is expected on or about September 23, 2026, subject to customary closing conditions, via a Rule 144A/Reg S private placement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
News
Rhea-AI Summary

IQVIA (IQV) plans to raise $2.0 billion through a private offering of senior notes due 2034 by its wholly owned subsidiary IQVIA Inc.

Net proceeds are expected to be used to redeem in full the Issuer’s existing Senior 5.000% Notes due 2026, repay a portion of borrowings under its revolving credit facility, and pay related fees and expenses. Completion of the offering is subject to market and other customary conditions. The notes are unregistered under the Securities Act and will be offered only to qualified institutional buyers in the United States under Rule 144A and to non-U.S. investors under Regulation S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
debt offering offering
-
Rhea-AI Summary

IQVIA (IQV) launched IQVIA Predictive Clinical Development, an AI-powered clinical development approach intended to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.

The offering applies Healthcare-grade AI® and proprietary data across the development lifecycle, delivering reported efficiency gains including 33% faster study startup, 1.7x more patients recruited from AI-prioritized Prime & Partner sites with 42% higher enrollment rates, 50% faster data cleaning and over 45% reduced time between trial phases. IQVIA combines its regulatory expertise with technologies from partners such as Anthropic, AWS, Databricks, Microsoft, NVIDIA, Palantir and Snowflake to orchestrate agentic AI workflows.

The platform is enabled by three main clinical AI capabilities: Clinical Design & Planning Suite for predictive site and enrollment planning, Push Button Start-Up for standardized and automated trial initiation, and Real-time Data Cleaning to integrate multi-source clinical data and support faster, higher quality decisions and database locks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
-
Rhea-AI Summary

IQVIA (NYSE:IQV) reported multiple 2026 industry awards recognizing its AI-driven platforms across clinical research, regulatory, privacy and healthcare operations. Honors include an American Business Awards® Gold Stevie® for the Literature AI Platform, MedTech Breakthrough’s Best Compliance Solution, two Silver Stevie® awards and an AI Breakthrough predictive modeling award.

According to IQVIA, its Literature AI Platform achieved 100% recall, ≥93% precision and >90% workload reduction. The Privacy Analytics Platform, used in England’s NHS Federated Data Platform, enabled 110,000+ extra procedures, 14.9% fewer discharge delays and supported 90,000+ cancer patients. Other recognized tools improved regulatory efficiency, trial drug supply and type 1 diabetes detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
AI
Rhea-AI Summary

IQVIA (NYSE:IQV) announced that its AI-enabled Clinical Decision Support Tool for diabetes, developed with Breakthrough T1D, has received the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. The solution uses IQVIA Healthcare-grade AI® to address frequent misclassification of adults with type 1 diabetes (T1D) as type 2 (T2D), which can delay appropriate treatment and increase complication risks.

In real-world use, the tool cut screening workload by 99.5%, shrinking manual reviews from about 60,000 patients to 300. It delivered an estimated 127x increase in diagnostic yield, with 28% of flagged patients confirmed or suspected T1D versus a 0.22% baseline, thereby accelerating accurate diagnosis and supporting better long-term outcomes. IQVIA said this award highlights its expanding portfolio of AI solutions aimed at solving complex clinical challenges and advancing human health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
AI

FAQ

What is the current stock price of IQVIA Holdings (IQV)?

IQVIA Holdings (IQV) last closed at $250.55.

What is the market cap of IQVIA Holdings (IQV)?

The market cap of IQVIA Holdings (IQV) is approximately $41.3B.